top of page
Browse by category
Search
First participants dosed in Ascletis’ 13-week Phase IIa study of oral GLP-1r agonist ASC30
The first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in Ascletis Pharma’s US...
Ring-augmented RYGB in patients with BMI≥50 leads to significant weight loss and improvement in obesity-related complications
Ring-augmented RYGB (raRYGB) with a MiniMizer Ring in patients with BMI≥50kg/m2, results in significant weight loss and improvements in...
Journal Watch 2/7/2025
Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
International expert consensus statements on surgery for T2DM
An International panel of experts has published 43 statements on the nature, terminology and mechanisms of action of metabolic and...
Rerouted bile acid reduces tumour spread in colorectal cancer mouse model
Bile acid diversion in Roux-en-Y gastric bypass (RYGB) reduces colorectal tumour growth and metastasis independent of weight loss,...
Protagonist selects PN-477 an oral and injectable triple agonist peptide development candidate for obesity
Protagonist Therapeutics has selected PN-477 a novel oral peptide - PN-477o with once-daily dosing, high potency and activation of...
Browse by tag
bottom of page